Compelling clinical evidence supports the biomarker as being predictive of resistance to a drug

R2

Level 1* **Companion Diagnostics**

Level 2

Cancer Mutations with Evidence of Clinical Significance

Level 3

Cancer Mutations with Potential Clinical Significance

FDA OncoKB

^{*} Note that FDA Level 1 is reserved specifically for Companion Diagnostics. For more information please see here.